Skip to main content

Allegro 3D

HardwareSan Diego, CA, USAFounded 2016· One of 1757 Hardware companies tracked by AMPulse

Develops DLP-based bioprinting technology for high-throughput manufacturing of biomedical devices, cell matrices, and precision human tissues for cell culture, drug screening, therapeutics, and regenerative medicine.

CEO / Founder
Wei Zhu
Team Size
1-10
Stage
Acquired
Total Funding
$7.23M
Latest Round
Acquired
Key Investors
Small Business Innovation Research Awards, BICO

Technology & Products

Key Products

STEMAKER™ (automated DLP bioprinter for direct printing in 6-, 12-, and 24-well plates, compatible with CT/MRI/CAD)

Technological Advantage

Proprietary DLP bioprinting process achieves high-speed, high-precision tissue constructs, protected by 1 patent (application 10/7/2021) covering lithography, microfabrication, microtechnology, and molecular biology.

Differentiation

Value Proposition

Enables direct fabrication of 3D tissues in a rapid high-throughput manner, reducing lead times and enabling scalable biofabricated constructs for in vivo-like models and reduced animal testing dependency.

How They Differentiate

3x faster build speed than traditional extrusion bioprinters for high-throughput tissue constructs, with proprietary DLP technology enabling direct printing in multi-well plates for scalable applications.

Market & Competition

Target Customers

Researchers in tissue engineering, regenerative medicine, precision medicine, disease modeling, and drug discovery

Industry Verticals

Biotechnology; Pharmaceuticals; Medical Research

Competitors

TheWell Bioscience; Bioactive Regenerative Therapeutics; Obatala Sciences

Growth & Milestones

Growth Metrics

Acquired by BICO for an upfront enterprise value of $6 million USD with $5 million earnout contingent on performance, projected 2022 revenue of ~$1 million and positive EBITDA.

Major Milestones

2016: Founded in San Diego, CA; Pre-2022: Raised $1.23M; developed patented DLP bioprinting; May 6, 2022: Acquired by BICO for $6M upfront + $5M earnout (total $11M); Post-acquisition: Technology integrated into BICO/CELLINK portfolio

https://allegro3d.com

Why this company matters

Allegro 3D develops DLP-based bioprinting technology for high-throughput manufacturing of biomedical devices, cell matrices, and precision human tissues. The company addresses the need for scalable biofabrication in cell culture, drug screening, therapeutics, and regenerative medicine, aiming to reduce reliance on animal testing by producing in vivo-like models.

The core product is the STEMAKER, an automated DLP bioprinter that prints directly into 6-, 12-, and 24-well plates and is compatible with CT, MRI, and CAD data. The proprietary DLP process achieves high-speed, high-precision tissue constructs, with a claimed build speed three times faster than traditional extrusion bioprinters. The technology is protected by a patent application covering lithography, microfabrication, microtechnology, and molecular biology.

Target customers include researchers in tissue engineering, regenerative medicine, precision medicine, disease modeling, and drug discovery. The company was acquired by BICO in May 2022 for an upfront enterprise value of $6 million plus a $5 million earnout, and its technology has been integrated into the CELLINK portfolio. Known competitors include TheWell Bioscience, Bioactive Regenerative Therapeutics, and Obatala Sciences.

Allegro 3D's strategic moat lies in its patented DLP bioprinting method for direct well-plate printing, which enables higher throughput than extrusion-based alternatives. A key open question is whether the technology can scale beyond research applications into clinical-grade tissue manufacturing, given the regulatory and reproducibility challenges inherent in bioprinted constructs.